DYNAVAX TECHNOLOGIES CORP (DVAX)

Company Profile

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 408 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. The company also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The company is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Company Info

DYNAVAX TECHNOLOGIES CORP

2100 Powell Street, Suite 720

Emeryville CALIFORNIA 94608

P: 15108485100

CEO: Ryan Spencer

Employees: 408

Website: https://www.dynavax.com/